You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 16, 2025

Patent: 10,149,901


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,149,901
Title:Influenza vaccines with reduced amounts of squalene
Abstract: Influenza vaccines include hemagglutinin from at least one influenza A virus strain and at least one influenza B virus strain. They also include an oil-in-water emulsion adjuvant with submicron oil droplets, comprising squalene. In some embodiments the hemagglutinin concentration is >12 .mu.g/ml per strain. In some embodiments the squalene concentration is <19 mg/ml. In some embodiments the vaccine is mercury-free. In some embodiments the vaccine has a unit dose volume between 0.2-0.3 mL. In some embodiments the squalene concentration is 9.75 mg/mL or 4.88 mg/mL. In some embodiments the vaccine includes antigens from two influenza A virus strains and two influenza B virus strains.
Inventor(s): Contorni; Mario (Siena, IT), O\'Hagan; Derek (Cambridge, MA), Groth; Nicola (Buonconvento, IT)
Assignee: Seqirus UK Limited (Berkshire, GB)
Application Number:15/007,719
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Understanding the U.S. Patent Landscape: A Comprehensive Analysis of Patent 10,149,901

Introduction

Patents are a cornerstone of innovation, providing inventors with exclusive rights to their inventions and encouraging the development of new technologies. This article delves into the complexities of the U.S. patent process, with a specific focus on the claims and landscape surrounding United States Patent 10,149,901. We will explore the patent process, the importance of patent claims, and the current landscape of patent law, particularly in the context of AI and other emerging technologies.

The U.S. Patent Process

The journey from an idea to a patented invention is rigorous and time-consuming. Here’s a breakdown of the key stages:

From Idea to Application

An invention begins as an idea that is developed into a patent application. This application must be filed with the United States Patent and Trademark Office (USPTO) and must describe the invention in sufficient detail for someone knowledgeable in the field to understand, make, and use it[1].

From Application to Evaluation

The patent application is then evaluated by a USPTO patent examiner, typically a skilled scientist or engineer, to ensure it meets the legal requirements of being novel, useful, and nonobvious. More than 85% of patent applications are rejected at least once, requiring applicants to address the examiner’s concerns through amendments or discussions[1].

From Application to Issuance

The process from application to issuance typically takes about two years. Once granted, the patent gives the inventor the exclusive right to make, use, sell, offer for sale, or import the invention for a period of 20 years from the filing date[1].

The Importance of Patent Claims

Patent claims are the legal descriptions of the aspects of the invention that are protected by law. These claims are crucial as they define the scope of the patent.

Crafting Effective Claims

Effective claims must be clear, concise, and specific. They should detail the innovative aspects of the invention and distinguish it from prior art. In the context of AI inventions, for example, claims must demonstrate a specific, concrete technological advancement or solution to a technical problem to overcome subject matter eligibility rejections under 35 U.S.C. § 101[2].

Subject Matter Eligibility and AI Inventions

The subject matter eligibility of AI inventions has been a focal point of recent patent law updates.

The Two-Pronged Framework

The USPTO has introduced a two-pronged framework for evaluating the subject matter eligibility of AI inventions. Prong One focuses on whether the claims recite abstract ideas, while Prong Two requires demonstrating that the claims are directed to a specific technological advancement or solution to a technical problem. The 2024 Guidance Update emphasizes the importance of Prong Two in overcoming section 101 rejections for AI inventions[2].

Practical Applicability Analysis

For AI inventions, the key to overcoming subject matter eligibility rejections lies in the practical applicability analysis under Prong Two. This involves demonstrating the real-world impact of the invention and its contribution to the technological field. Practitioners should focus on crafting compelling narratives that highlight the innovation’s practical applicability[2].

Patent Assertion Entities (PAEs)

PAEs, also known as patent trolls, play a significant role in the patent landscape.

Business Models of PAEs

The FTC study identified two distinct business models for PAEs: Portfolio PAEs and Litigation PAEs. Portfolio PAEs negotiate licenses covering large portfolios of patents without first suing the alleged infringer, while Litigation PAEs focus on suing for patent infringement before licensing. Litigation PAEs account for the majority of licenses but generate less revenue compared to Portfolio PAEs[3].

Impact of PAEs

PAEs can have significant implications for various industries, including retail and technology. They often assert patents against firms in multiple sectors, leading to substantial litigation and licensing activities. The FTC study highlighted that PAEs generate significant revenue through these activities, with Portfolio PAEs generating approximately $3.2 billion during the study period[3].

Use of AI Tools in Patent Applications

The increasing use of AI tools in patent applications introduces new complexities.

Disclosure Requirements

If AI tools are used in the drafting of patent applications, this must be disclosed to the USPTO. This includes any evidence that the AI system made significant contributions to the invention, potentially affecting the inventorship of the claimed invention[5].

Ensuring Accuracy

Practitioners must verify the accuracy of all documents prepared with AI assistance to ensure they do not introduce inaccurate statements or omit material information. This is crucial for maintaining the integrity of the patent application process[5].

Patent 10,149,901: A Case Study

While specific details about Patent 10,149,901 are not provided here, we can apply the general principles discussed above to analyze its claims and place it within the broader patent landscape.

Claims Analysis

To analyze the claims of Patent 10,149,901, one would need to review the patent specification and claims to determine their scope and novelty. This involves checking if the claims are clear, specific, and distinguishable from prior art.

Subject Matter Eligibility

If the patent involves AI or other emerging technologies, it would be essential to evaluate its subject matter eligibility under the two-pronged framework. This includes assessing whether the claims demonstrate a specific technological advancement or solution to a technical problem.

Patent Assertion and Licensing

Understanding whether the patent is held by a PAE or an operating company can provide insights into its potential impact on the market. If it is held by a PAE, analyzing its business model (whether it is a Portfolio PAE or a Litigation PAE) can help predict how the patent might be asserted and licensed.

Key Takeaways

  • Patent Process: The U.S. patent process is rigorous, involving extensive evaluation by USPTO examiners to ensure the invention meets legal requirements.
  • Patent Claims: Effective claims are crucial and must clearly define the innovative aspects of the invention.
  • AI Inventions: AI inventions face specific challenges under subject matter eligibility analysis, with a focus on demonstrating practical applicability.
  • PAEs: PAEs play a significant role in the patent landscape, with different business models impacting how patents are asserted and licensed.
  • AI Tools: The use of AI tools in patent applications requires careful disclosure and verification to maintain the integrity of the process.

FAQs

Q: How long does it typically take to get a patent granted in the U.S.? A: The process from patent application to issuance typically takes about two years.

Q: What are the key requirements for a patent to be granted? A: The invention must be novel, useful, and nonobvious.

Q: How do PAEs impact the patent landscape? A: PAEs can significantly impact various industries through their assertion and licensing activities, often leading to substantial litigation and revenue generation.

Q: What is the significance of Prong Two in the subject matter eligibility analysis for AI inventions? A: Prong Two requires demonstrating that the claims are directed to a specific technological advancement or solution to a technical problem, which is critical for overcoming section 101 rejections.

Q: Why is disclosure important when using AI tools in patent applications? A: Disclosure is necessary to ensure that any contributions made by AI systems are acknowledged and to verify the accuracy of the patent application.

Sources

  1. PhRMA, "IP Explained: How does the U.S. patent process work?" (2021).
  2. Baker Botts, "The Importance of Prong Two of Step 2A for AI Inventions" (2024).
  3. FTC, "Patent Assertion Entity Activity: An FTC Study" (PDF).
  4. Brown University Library, "Home - Patents - Library Guides at Brown University" (2023).
  5. Buchanan Ingersoll & Rooney PC, "U.S. Patent Office Issues Additional Guidance on Use of AI Tools" (2024).

More… ↓

⤷  Try for Free

Details for Patent 10,149,901

ApplicantTradenameBiologic IngredientDosage FormBLAApproval DatePatent No.Expiredate
Seqirus Vaccines Limited FLUVIRIN influenza virus vaccine Injection 103837 November 03, 1998 10,149,901 2029-02-10
Sanofi Pasteur Inc. FLUZONE, FLUZONE HD QUADRIVALENT, FLUZONE HIGH DOSE, FLUZONE INTRADERMAL, FLUZONE QUADRIVALENT influenza virus vaccine Injection 103914 December 09, 1999 10,149,901 2029-02-10
Sanofi Pasteur Inc. FLUZONE, FLUZONE HD QUADRIVALENT, FLUZONE HIGH DOSE, FLUZONE INTRADERMAL, FLUZONE QUADRIVALENT influenza virus vaccine Injection 103914 December 23, 2009 10,149,901 2029-02-10
Sanofi Pasteur Inc. FLUZONE, FLUZONE HD QUADRIVALENT, FLUZONE HIGH DOSE, FLUZONE INTRADERMAL, FLUZONE QUADRIVALENT influenza virus vaccine Injection 103914 May 09, 2011 10,149,901 2029-02-10
>Applicant>Tradename>Biologic Ingredient>Dosage Form>BLA>Approval Date>Patent No.>Expiredate
Showing 1 to 4 of 4 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.